Progress of immune checkpoint inhibitors for the treatment of myelodysplastic syndrome
Immune checkpoint inhibitor(ICI) is a potential treatment for MDS by inhibiting the escape of tumor cells and enhancing immune responses. This article reviewed the efficacy and adverse events of clinical trials focusing on PD-1/PD-L1 and CTLA-4 inhibitors on MDS patients. Although the efficacy of si...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Institute of Basic Medical Sciences and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences / Peking Union Medical College.
2021-08-01
|
| Series: | Jichu yixue yu linchuang |
| Subjects: | |
| Online Access: | http://journal11.magtechjournal.com/Jwk_jcyxylc/fileup/1001-6325/PDF/a200584.pdf |
| _version_ | 1797365828319969280 |
|---|---|
| author | ZHANG Ruo-xi, HAN Bing |
| author_facet | ZHANG Ruo-xi, HAN Bing |
| author_sort | ZHANG Ruo-xi, HAN Bing |
| collection | DOAJ |
| description | Immune checkpoint inhibitor(ICI) is a potential treatment for MDS by inhibiting the escape of tumor cells and enhancing immune responses. This article reviewed the efficacy and adverse events of clinical trials focusing on PD-1/PD-L1 and CTLA-4 inhibitors on MDS patients. Although the efficacy of single-agent ICI therapy was limited, it may have a synergistic effect with hypomethylation agent (HMA), which could be a choice for patients who fail to respond to HMA treatment. Immune-related adverse events(irAE) were observed, but most can be reversed by steroids. |
| first_indexed | 2024-03-08T16:54:31Z |
| format | Article |
| id | doaj.art-fb79d87d18c64f429bdb95665e632723 |
| institution | Directory Open Access Journal |
| issn | 1001-6325 |
| language | zho |
| last_indexed | 2024-03-08T16:54:31Z |
| publishDate | 2021-08-01 |
| publisher | Institute of Basic Medical Sciences and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences / Peking Union Medical College. |
| record_format | Article |
| series | Jichu yixue yu linchuang |
| spelling | doaj.art-fb79d87d18c64f429bdb95665e6327232024-01-05T03:06:25ZzhoInstitute of Basic Medical Sciences and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences / Peking Union Medical College.Jichu yixue yu linchuang1001-63252021-08-0141812101215Progress of immune checkpoint inhibitors for the treatment of myelodysplastic syndromeZHANG Ruo-xi, HAN Bing0Department of Hematology, Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730, ChinaImmune checkpoint inhibitor(ICI) is a potential treatment for MDS by inhibiting the escape of tumor cells and enhancing immune responses. This article reviewed the efficacy and adverse events of clinical trials focusing on PD-1/PD-L1 and CTLA-4 inhibitors on MDS patients. Although the efficacy of single-agent ICI therapy was limited, it may have a synergistic effect with hypomethylation agent (HMA), which could be a choice for patients who fail to respond to HMA treatment. Immune-related adverse events(irAE) were observed, but most can be reversed by steroids.http://journal11.magtechjournal.com/Jwk_jcyxylc/fileup/1001-6325/PDF/a200584.pdfimmune checkpoint inhibitor|myelodysplastic syndrome|efficacy|safety |
| spellingShingle | ZHANG Ruo-xi, HAN Bing Progress of immune checkpoint inhibitors for the treatment of myelodysplastic syndrome Jichu yixue yu linchuang immune checkpoint inhibitor|myelodysplastic syndrome|efficacy|safety |
| title | Progress of immune checkpoint inhibitors for the treatment of myelodysplastic syndrome |
| title_full | Progress of immune checkpoint inhibitors for the treatment of myelodysplastic syndrome |
| title_fullStr | Progress of immune checkpoint inhibitors for the treatment of myelodysplastic syndrome |
| title_full_unstemmed | Progress of immune checkpoint inhibitors for the treatment of myelodysplastic syndrome |
| title_short | Progress of immune checkpoint inhibitors for the treatment of myelodysplastic syndrome |
| title_sort | progress of immune checkpoint inhibitors for the treatment of myelodysplastic syndrome |
| topic | immune checkpoint inhibitor|myelodysplastic syndrome|efficacy|safety |
| url | http://journal11.magtechjournal.com/Jwk_jcyxylc/fileup/1001-6325/PDF/a200584.pdf |
| work_keys_str_mv | AT zhangruoxihanbing progressofimmunecheckpointinhibitorsforthetreatmentofmyelodysplasticsyndrome |